Literature DB >> 9682830

The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations.

F Crawford1, D Fallin, Z Suo, L Abdullah, M Gold, A Gauntlett, R Duara, M Mullan.   

Abstract

The K variant of the butyrylcholinesterase gene (BChE) was recently found to occur at an increased frequency in a late onset Alzheimer's disease (AD) population, specifically in individuals carrying the epsilon4 allele of the apolipoprotein E (APOE) gene. This suggested synergy between these two genes resulting in an increased risk of late-onset AD. We have genotyped 62 community-based and 329 clinic-based AD cases, and 201 community-based controls at BChE and APOE and find no independent association between BChE and AD nor interaction with APOE in risk for AD in either our clinic or community-based samples.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682830     DOI: 10.1016/s0304-3940(98)00423-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  GAB2 gene does not modify the risk of Alzheimer's disease in Spanish APOE 4 carriers.

Authors:  R Ramirez-Lorca; M Boada; M E Saez; I Hernandez; A Mauleon; M Rosende-Roca; P Martinez-Lage; M Gutierrez; L M Real; J Lopez-Arrieta; J Gayan; C Antunez; A Gonzalez-Perez; L Tarraga; A Ruiz
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

2.  Association of BDNF and BCHE with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls.

Authors:  Huihui Ji; Dongjun Dai; Yunliang Wang; Danjie Jiang; Xingyu Zhou; Peipei Lin; Xiaosui Ji; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Rongrong Chen; Lina Zhang; Mingqing Xu; Shiwei Duan; Qinwen Wang
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

3.  Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.

Authors:  K M Mattila; J O Rinne; M Röyttä; P Laippala; T Pietilä; H Kalimo; T Koivula; H Frey; T Lehtimäki
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

4.  Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland.

Authors:  S P McIlroy; V L Crawford; K B Dynan; B M McGleenon; M D Vahidassr; J T Lawson; A P Passmore
Journal:  J Med Genet       Date:  2000-03       Impact factor: 6.318

5.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

6.  Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.

Authors:  Zongcheng Wang; Yuren Jiang; Xi Wang; Yangsen Du; Dandan Xiao; Youchao Deng; Jinlian Wang
Journal:  Med Sci Monit       Date:  2015-05-16

7.  Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.

Authors:  Jacek Jasiecki; Anna Limon-Sztencel; Monika Żuk; Magdalena Chmara; Dominik Cysewski; Janusz Limon; Bartosz Wasąg
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.